Protagen Expands Cooperation with Bayer HealthCare

09-Dec-2011 - Germany

Protagen AG and Bayer HealthCare Pharmaceuticals announced the start of a new collaboration project for the clinical validation of diagnostic biomarkers in endometriosis. This new cooperation project builds on the results of the Endometriosis biomarker discovery study performed last year, and is already the third UNIarray® Project within the collaboration between the two partners in the last three years.

„With the targeted advancement of the UNIarray® technology platform, Protagen has developed into a preferred partner for drug development companies”, states Dr. Peter Schulz-Knappe, CSO and Executive Vice President Diagnostics at Protagen, „now we can directly support our collaboration partners in pharma and biotech in all clinical Phases I-IV with the development of therapy specific diagnostic assays.
Besides Endometriosis, our technology is applied in autoimmune diseases like Multiple Sclerosis, chronic inflammatory diseases and cancer. Cooperation partners are, amongst others, Bayer, Biogen-Idec und SuppreMol.“

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances